Swieczkowski D
Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
ArticleDMT
Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.
ArticleMDMA
Exploring Attitudes Toward MDMA-Assisted Therapy in Mental Health Care
ArticleKetamine
Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations.
ArticlePsilocybin
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.
ArticleKetamine
Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.
ArticlePsychedelics
Regulatory context for protocol amendments and public reporting in psychedelic trials.
ArticleKetamine
Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.
ArticlePsilocybin
Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols.
ArticlePsilocybin
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.
ArticleDMT
Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.
ArticleKetamine
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
ArticlePsilocybin
Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.
ArticleIbogaine
Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.
ArticlePsilocybin
Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.
ArticlePsilocybin